The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Targeting CALR with immunotherapy in MPNs
Johannes Foßelteder, Medical University of Graz, Graz, Austria, comments on the potential of targeting calreticulin (CALR)-mutated myeloproliferative neoplasm (MPN) progenitors with a neoepitope-directed monoclonal antibody and with T-cells engineered to target CALR. Recent evidence from experiments in in vitro and in vivo models has shown that monoclonal antibodies and T-cells engineered to target CALR induce efficient killing of mutant cells. This interview took place virtually.
